These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9192975)

  • 21. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
    Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
    Chi KH; Kunugi KA; Kinsella TJ
    Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
    Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
    Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
    Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
    Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
    Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
    Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
    Los G; van Vugt MJ; den Engelse L; Pinedo HM
    Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum (II) does not correlate with the platination level or with the formation or removal of DNA adducts.
    Vendrik CP; Fichtinger-Schepman AM; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; de Groot G; Berends GF; Steerenberg PA
    Cancer Chemother Pharmacol; 1997; 39(6):479-85. PubMed ID: 9118458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
    Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M
    Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.
    de Jong S; Timmer-Bosscha H; de Vries EG; Mulder NH
    Int J Cancer; 1993 Jan; 53(1):110-7. PubMed ID: 8380054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.
    Morikage T; Ohmori T; Nishio K; Fujiwara Y; Takeda Y; Saijo N
    Cancer Res; 1993 Jul; 53(14):3302-7. PubMed ID: 8391922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
    Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
    Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
    Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of cellular cisplatin resistance by hyperthermia--a review.
    Hettinga JV; Konings AW; Kampinga HH
    Int J Hyperthermia; 1997; 13(5):439-57. PubMed ID: 9354931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
    Teicher BA; Holden SA; Herman TS; Sotomayor EA; Khandekar V; Rosbe KW; Brann TW; Korbut TT; Frei E
    Int J Cancer; 1991 Jan; 47(2):252-60. PubMed ID: 1846350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
    Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
    Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.